Evidence map›Paper›PMID 41458280›Full record

ArticleOxford medical case reports2025

Acute Promyelocytic Leukemia with double minute chromosomes: a rare case with high relapse risk.

Yohei Sasaki, Shotaro Shimada, Natsuki Kawamata, Hidenori Hayashi, Kazuki Nagao, Kai Kuroiwa, Hinako Narita, Reiko Okamura, Megumi Watanuki, Nana Arai and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yohei SasakiDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.ORCID https://orcid.org/0009-0000-4215-2094
Shotaro ShimadaDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Natsuki KawamataDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Hidenori HayashiDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Kazuki NagaoDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Kai KuroiwaDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Hinako NaritaDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Reiko OkamuraDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Megumi WatanukiDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Nana AraiDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Kouji YanagisawaDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.
Norimichi HattoriDivision of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML); it has a high response rate and long-term survival with differentiation therapy and chemotherapy. However, only one previous case of APL with double minute chromosomes (DMs, a poor prognostic factor for AML) has been reported. We report the case of a patient with APL and DMs. A 44-year-old woman was treated with all-trans retinoic acid (ATRA) and chemotherapy and achieved molecular complete remission (mCR). However, the condition relapsed after 15 months. She was treated with arsenic trioxide and autologous transplantation and experienced mCR. Her peripheral blood was positive for minimal residual disease (MRD) 2 months after autologous transplantation. She became MRD-negative with ATRA and has maintained the negative status for 15 months. This is the first report to suggest that patients with APL and DMs may be a high-risk group for relapse and benefit from maintaining with ATRA.

Indexed as

acute promyelocytic leukemiadifferentiation therapydouble minutes chromosomesrelapse

Identifiers

PMID41458280
PMCPMC12741448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.